Later, rescue experiments using SN50 and the PI3K/AKT signaling inhibitor PI3K-IN-1 revealed that suppression of NF-κB or impairment of the PI3K/AKT signaling could effectively counteract the oncogenic role of CCND1 in lung cancer in vitro and in vivo. This evidence concerns the gene AKT1 and lung cancer.